QurAlis: Raises $42M in Series A Financing
- The company focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD)
- The funding round was also led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery Fund
- FTD is an uncommon type of dementia that causes problems with behavior and language and primarily affects the frontal and temporal lobes of the brain
- It tends to hit middle-aged people and can misdiagnosed as Alzheimer’s disease
- Recent advances in science and technology have also identified strong disease targets for specific groups of ALS and FTD patients
- Then the QurAlis team built this company from the ground up on a foundation of cutting-edge science
